Company & Sponsor Intelligence
Supernus Pharmaceuticals, Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials20
Recruiting3
Completed15
Countries2
Therapeutic footprint
adhdalzheimersdepressionepilepsyparkinsons
Indexed studies
NCT04476017A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)
parkinsons · United StatesPHASE2
parkinsons · United StatesPHASE2
NCT03247543Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD
adhd · United StatesPHASE3
adhd · United StatesPHASE3
NCT01416064Open-Label, Extension Study to 810P202
adhd · United StatesPHASE2
adhd · United StatesPHASE2
NCT04143217Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
adhd · United StatesPHASE3
adhd · United StatesPHASE3
NCT00918047Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients
epilepsy · United StatesPHASE1
epilepsy · United StatesPHASE1
NCT05619692A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT03247556Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD
adhd · United StatesPHASE3
adhd · United StatesPHASE3
NCT04781140Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
adhd · United StatesPHASE4
adhd · United StatesPHASE4
NCT04016792Classroom Study of SPN-812 in Children With ADHD
adhd · PHASE3
adhd · PHASE3
NCT00908349Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
epilepsy · United StatesPHASE3
epilepsy · United StatesPHASE3
NCT06185985Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
adhd · United StatesPHASE4
adhd · United StatesPHASE4
NCT06798896RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
epilepsy · United StatesPHASE2
epilepsy · United StatesPHASE2
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →